TSH Biopharm Corporation Limited (TPEX:8432)
50.30
-0.10 (-0.20%)
May 12, 2025, 1:30 PM CST
TSH Biopharm Corporation Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Revenue | 1,202 | 1,116 | 810.92 | 741.07 | 413.48 | 447.86 | Upgrade
|
Revenue Growth (YoY) | 38.75% | 37.59% | 9.43% | 79.22% | -7.68% | -11.78% | Upgrade
|
Cost of Revenue | 593.55 | 532.95 | 411.02 | 351.2 | 166.13 | 162.67 | Upgrade
|
Gross Profit | 608.79 | 582.76 | 399.9 | 389.87 | 247.36 | 285.19 | Upgrade
|
Selling, General & Admin | 413.58 | 384.16 | 313.39 | 289.71 | 168.33 | 182.31 | Upgrade
|
Research & Development | 25.91 | 27.99 | 24.81 | 31.09 | 23.52 | 28.68 | Upgrade
|
Operating Expenses | 440.28 | 412.91 | 336.27 | 323.85 | 191.74 | 210.89 | Upgrade
|
Operating Income | 168.51 | 169.86 | 63.63 | 66.03 | 55.62 | 74.3 | Upgrade
|
Interest Expense | -0.63 | -0.46 | -0.69 | -0.7 | -0.08 | -0.03 | Upgrade
|
Interest & Investment Income | 12.57 | 11.98 | 13.06 | 9.71 | 8.46 | 8.66 | Upgrade
|
Currency Exchange Gain (Loss) | 0.33 | 0.33 | -0.43 | 6.39 | -1.26 | 0.41 | Upgrade
|
Other Non Operating Income (Expenses) | 1.96 | 1.39 | 0.56 | -0.13 | -1.23 | -4.55 | Upgrade
|
EBT Excluding Unusual Items | 182.74 | 183.1 | 76.13 | 81.3 | 61.51 | 78.79 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | - | - | -1.56 | Upgrade
|
Gain (Loss) on Sale of Assets | -0.87 | -0.87 | -0.04 | -0.06 | -0 | - | Upgrade
|
Asset Writedown | -8.8 | -8.8 | - | - | - | - | Upgrade
|
Other Unusual Items | - | - | - | - | 0.05 | - | Upgrade
|
Pretax Income | 173.08 | 173.43 | 76.09 | 81.24 | 61.55 | 77.23 | Upgrade
|
Income Tax Expense | 38.12 | 39.29 | 11.11 | 15.1 | 14.44 | 15.66 | Upgrade
|
Earnings From Continuing Operations | 134.96 | 134.15 | 64.98 | 66.14 | 47.11 | 61.57 | Upgrade
|
Minority Interest in Earnings | -32.38 | -21.06 | -2.99 | -4.25 | - | - | Upgrade
|
Net Income | 102.58 | 113.09 | 61.99 | 61.89 | 47.11 | 61.57 | Upgrade
|
Net Income to Common | 102.58 | 113.09 | 61.99 | 61.89 | 47.11 | 61.57 | Upgrade
|
Net Income Growth | 11.21% | 82.44% | 0.16% | 31.38% | -23.49% | -27.84% | Upgrade
|
Shares Outstanding (Basic) | 38 | 38 | 38 | 38 | 38 | 38 | Upgrade
|
Shares Outstanding (Diluted) | 38 | 38 | 38 | 38 | 38 | 38 | Upgrade
|
Shares Change (YoY) | 0.06% | 0.04% | -0.05% | 0.05% | 0.01% | - | Upgrade
|
EPS (Basic) | 2.67 | 2.95 | 1.61 | 1.61 | 1.23 | 1.60 | Upgrade
|
EPS (Diluted) | 2.67 | 2.94 | 1.61 | 1.61 | 1.23 | 1.60 | Upgrade
|
EPS Growth | 11.54% | 82.61% | - | 31.23% | -23.32% | -27.93% | Upgrade
|
Free Cash Flow | 154.13 | 182.04 | 28.49 | 30.62 | 68.33 | 9.7 | Upgrade
|
Free Cash Flow Per Share | 4.01 | 4.74 | 0.74 | 0.80 | 1.78 | 0.25 | Upgrade
|
Dividend Per Share | - | 2.120 | 1.280 | 1.600 | 1.500 | 1.800 | Upgrade
|
Dividend Growth | - | 65.63% | -20.00% | 6.67% | -16.67% | - | Upgrade
|
Gross Margin | 50.63% | 52.23% | 49.31% | 52.61% | 59.82% | 63.68% | Upgrade
|
Operating Margin | 14.02% | 15.22% | 7.85% | 8.91% | 13.45% | 16.59% | Upgrade
|
Profit Margin | 8.53% | 10.14% | 7.64% | 8.35% | 11.39% | 13.75% | Upgrade
|
Free Cash Flow Margin | 12.82% | 16.32% | 3.51% | 4.13% | 16.52% | 2.17% | Upgrade
|
EBITDA | 184.46 | 185.11 | 77.65 | 79.28 | 60.87 | 79.66 | Upgrade
|
EBITDA Margin | 15.34% | 16.59% | 9.58% | 10.70% | 14.72% | 17.79% | Upgrade
|
D&A For EBITDA | 15.96 | 15.26 | 14.02 | 13.25 | 5.26 | 5.35 | Upgrade
|
EBIT | 168.51 | 169.86 | 63.63 | 66.03 | 55.62 | 74.3 | Upgrade
|
EBIT Margin | 14.02% | 15.22% | 7.85% | 8.91% | 13.45% | 16.59% | Upgrade
|
Effective Tax Rate | 22.02% | 22.65% | 14.61% | 18.58% | 23.46% | 20.28% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.